Skip to main content
Premium Trial:

Request an Annual Quote

Vector Labs Acquires Quanta BioDesign

NEW YORK – Proteomic and glycomic research tool provider Vector Laboratories said Monday it has acquired Quanta BioDesign for an undisclosed amount.

With the purchase, Newark, California-based Vector acquires a range of cross-linking and labeling chemistries based on Quanta's discrete polyethylene glycol (dPEG) technology, which it said will allow it to support new approaches in therapeutic and diagnostic development.

"This acquisition is valuable because it supports Vector Laboratories' long-term strategic vision of accelerating the pace of scientific discovery for life science companies and transformational treatments and approaches for biopharma companies," Vector CEO Lisa Sellers said in a statement.

The deal follows Vector's acquisition earlier this year of Click Chemistry Tools, a manufacturer of click chemistry linkers and labeling reagents, and Fluoroprobes, a manufacturer of fluorescent probes and dyes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.